<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_raon-2017-0055_s_006_w2aab3b7b7b1b6b1aab1c18b1Aa"><h3>Background</h3><p><italic>Helicobacter pylori (H. pylori)</italic> is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. <italic>H. pylori</italic> is a grade I carcinogen, responsible for the development of 89 % of noncardia gastric cancers. In the present study we analyzed the data for <italic>H. pylori</italic> eradication treatments in Slovenia.</p></sec><sec id="j_raon-2017-0055_s_007_w2aab3b7b7b1b6b1aab1c18b2Aa"><h3>Patients and methods</h3><p>Slovenia is a part of the European Registry on Helicobacter pylori Management from the beginning. In seven medical institutions data for <italic>H. pylori</italic> eradication treatments was collected for 1774 patients from April 16<sup>th</sup> 2013 to May 15<sup>th</sup> 2016. For further modified intention to treat (mITT) analysis 1519 patients were eligible and for per protocol (PP) analysis 1346 patients.</p></sec><sec id="j_raon-2017-0055_s_008_w2aab3b7b7b1b6b1aab1c18b3Aa"><h3>Results</h3><p>Patients’ dropout was 11.4%. Eradication rate for 7 day triple therapy with proton pump inhibitor (PPI) + Clarithromycin (C) + Amoxicillin (A) was 88.7% PP and 72.0% mITT; for PPI + C + Metronidazole (M) 85.2% PP and 84.4% mITT. Second line 14 day therapy PPI + A + Levofloxacin had 92.3% eradication rate PP and 87.1% mITT. Ten to fourteen day Bismuth quadruple therapy was the therapy in difficult to treat patients. At the end all patients that adhered to prescribed regimens were cured of their <italic>H. pylori</italic> infection.</p></sec><sec id="j_raon-2017-0055_s_009_w2aab3b7b7b1b6b1aab1c18b4Aa"><h3>Conclusions</h3><p>High dropout rate deserves further analysis. Slovenia is still a country with &lt; 15% <italic>H. pylori</italic> resistance to clarithromycin, triple therapy with PPI plus two antibiotics reaches PP eradication rate > 85%, but mITT eradication rates are suboptimal.</p></sec></abstract>

BackgroundHelicobacter pylori (H. pylori) is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. H. pylori is a grade I carcinogen, responsible for the development of 89 % of noncardia gastric cancers. In the present study we analyzed the data for H. pylori eradication treatments in Slovenia.Patients and methodsSlovenia is a part of the European Registry on Helicobacter pylori Management from the beginning. In seven medical institutions data for H. pylori eradication treatments was collected for 1774 patients from April 16th 2013 to May 15th 2016. For further modified intention to treat (mITT) analysis 1519 patients were eligible and for per protocol (PP) analysis 1346 patients.ResultsPatients’ dropout was 11.4%. Eradication rate for 7 day triple therapy with proton pump inhibitor (PPI) + Clarithromycin (C) + Amoxicillin (A) was 88.7% PP and 72.0% mITT; for PPI + C + Metronidazole (M) 85.2% PP and 84.4% mITT. Second line 14 day therapy PPI + A + Levofloxacin had 92.3% eradication rate PP and 87.1% mITT. Ten to fourteen day Bismuth quadruple therapy was the therapy in difficult to treat patients. At the end all patients that adhered to prescribed regimens were cured of their H. pylori infection.ConclusionsHigh dropout rate deserves further analysis. Slovenia is still a country with < 15% H. pylori resistance to clarithromycin, triple therapy with PPI plus two antibiotics reaches PP eradication rate > 85%, but mITT eradication rates are suboptimal.

Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management

Radiology and Oncology

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

BackgroundHelicobacter pylori (H. pylori) is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. H. pylori is a grade I carcinogen, responsible for the development of 89 % of noncardia gastric cancers. In the present study we analyzed the data for H. pylori eradication treatments in Slovenia.Patients and methodsSlovenia is a part of the European Registry on Helicobacter pylori Management from the beginning. In seven medical institutions data for H. pylori eradication treatments was collected for 1774 patients from April 16th 2013 to May 15th 2016. For further modified intention to treat (mITT) analysis 1519 patients were eligible and for per protocol (PP) analysis 1346 patients.ResultsPatients’ dropout was 11.4%. Eradication rate for 7 day triple therapy with proton pump inhibitor (PPI) + Clarithromycin (C) + Amoxicillin (A) was 88.7% PP and 72.0% mITT; for PPI + C + Metronidazole (M) 85.2% PP and 84.4% mITT. Second line 14 day therapy PPI + A + Levofloxacin had 92.3% eradication rate PP and 87.1% mITT. Ten to fourteen day Bismuth quadruple therapy was the therapy in difficult to treat patients. At the end all patients that adhered to prescribed regimens were cured of their H. pylori infection.ConclusionsHigh dropout rate deserves further analysis. Slovenia is still a country with  85%, but mITT eradication rates are suboptimal.

BackgroundHelicobacter pylori (H. pylori) is the most common chronic bacterial infection in the world affecting over 50% of the world’s population. H. pylori...

Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management

Article Category: Research Article

Published Online: Dec 07, 2017

Page range: 1 - 6

Received: Sep 11, 2017

Accepted: Nov 05, 2017

DOI: https://doi.org/10.1515/raon-2017-0055

© 2018 Bojan Tepes, Marko Kastelic, Miroslav Vujasinovic, Polona Lampic, Maja Seruga, Natasa Brglez Jurecic, Olga P. Nyssen, Maria G. Donday, Colm O’Morain, Francis Megraud, Adrian G McNicholl, Javier P. Gisbert

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.